Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The MDM2-p53 interaction.

Ute M Moll1, Oleksi Petrenko

  • 1Department of Pathology, State University of New York at Stony Brook, Stony Brook, NY 11794-8691, USA. umoll@notes.cc.sunysb.edu

Molecular Cancer Research : MCR
|January 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Editorial Expression of Concern: p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity.

Cell research·2025
Same author

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Cell death and differentiation·2025
Same author

Intratumor heterogeneity in KRAS signaling shapes treatment resistance.

iScience·2025
Same author

Editor's Note: Mitochondrially Targeted p53 Has Tumor Suppressor Activities In vivo.

Cancer research·2025
Same author

Corrigendum: TAp73 is a central transcriptional regulator of airway multiciliogenesis.

Genes & development·2024
Same journal

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same journal

Comprehensive multi-omic profiling of desmoplastic small round cell tumors identifies targetable pathways with therapeutic opportunities.

Molecular cancer research : MCR·2026
Same journal

CELF2 is a tumor suppressor that modulates SLC7A11 and promotes ferroptosis in stomach adenocarcinoma.

Molecular cancer research : MCR·2026
Same journal

MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer.

Molecular cancer research : MCR·2026
Same journal

Ceramide-induced endoplasmic reticulum stress reveals a targetable vulnerability in endocrine therapy-resistant breast cancer.

Molecular cancer research : MCR·2026
Same journal

Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells.

Molecular cancer research : MCR·2026
See all related articles

The p53 protein guards against damaged cells, but MDM2 inhibits its function. Disrupting the p53-MDM2 interaction is a key strategy for activating p53 and developing new cancer therapies.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Biochemistry

Background:

  • The p53 protein is a crucial tumor suppressor that halts the proliferation of cells with DNA damage.
  • MDM2 acts as the primary antagonist to p53, ubiquitinating and degrading it in unstressed cells.
  • The p53-MDM2 interaction is a tightly regulated, conformation-based process essential for cellular homeostasis.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying the p53-MDM2 interaction.
  • To explore the potential of targeting the p53-MDM2 complex for cancer therapy.
  • To understand how disrupting this interaction leads to p53 activation.

Main Methods:

  • Structural and functional analysis of the p53-MDM2 complex.
  • Biochemical assays to study protein-protein interactions.

Related Experiment Videos

  • Development and testing of small molecules designed to disrupt the p53-MDM2 binding.

    • Main Results:

    • The p53-MDM2 interaction is conformation-dependent and regulated at multiple levels.
    • Disruption of the p53-MDM2 complex is a critical event for p53 activation.
    • Small lipophilic molecules capable of disrupting the p53-MDM2 interaction have been designed.

    Conclusions:

    • The p53-MDM2 interaction is a validated target for cancer therapeutics.
    • Targeting this interaction can lead to the induction of p53 and its tumor-suppressive functions.
    • Further development of small molecules disrupting p53-MDM2 binding holds promise for novel cancer treatments.